Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Arnon Karni
41 années d'expérience
La clinique est certifiée :
En Israël, la plasmaphérèse coûte généralement entre $2,200 et $3,400. Le tarif final dépend de la pathologie, du diagnostic et du standing de la clinique. Les patients économisent environ 4% par rapport à la France, dont le prix moyen est $2,300. Les soins sont principalement dispensés dans des pôles médicaux majeurs comme Tel Aviv.
Avis d'expert Bookimed : Choisir un centre multidisciplinaire comme le Sourasky Medical Center (Ichilov) offre un excellent rapport qualité-prix. Cet établissement accrédité JCI intègre la plasmaphérèse à des services spécialisés comme la neurologie ou l'hématologie. Des experts comme le docteur Amnon Mosek utilisent ces techniques pour des cas complexes résistants aux traitements classiques. Bien qu'un forfait diagnostique coûte environ 6 800 €, il garantit un plan de soin précis dans l'un des dix meilleurs hôpitaux au monde.
Pourquoi choisir Israël pour la plasmaphérèse ?
Accédez à des solutions avancées de plasmaphérèse dans des cliniques de confiance .
Bookimed ne facture pas de frais supplémentaires pour les prix des Plasmaphérèse. Les tarifs sont issus des listes de prix officielles des cliniques. Vous payez directement à la clinique lors de votre arrivée pour votre Plasmaphérèse.
Bookimed s'engage pour votre sécurité. Nous ne travaillons qu'avec des établissements médicaux qui respectent des normes internationales élevées dans Plasmaphérèse et qui possèdent les licences nécessaires pour accueillir des patients internationaux dans le monde entier.
Bookimed offre une assistance experte gratuite. Un coordinateur médical personnel vous accompagne avant, pendant et après votre traitement, en résolvant tous les problèmes. Vous n'êtes jamais seul dans votre parcours de Plasmaphérèse.
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Le Dr Amnon est spécialisé en plasmaphérèse au Centre Médical Sourasky (Ichilov) et propose des traitements avancés pour des pathologies complexes.
Dr. Pazit Beckerman is a nephrologist with over 24 years of clinical practice in Israel. She specializes in chronic kidney disease (CKD), acute kidney injury (AKI), hemodialysis and peritoneal dialysis, hypertension-related kidney disease, glomerular diseases and proteinuria, electrolyte disorders, and kidney involvement in systemic diseases.
She served as Acting Director in 2020, Deputy Director from 2018 to 2020, and Senior Physician in the Department of Nephrology at Sheba Medical Center. She also heads the Israeli Dialysis Registry.
Education and training: MD, Hebrew University–Hadassah. Nephrology residency, Hadassah. Fellowship in nephrology, Sheba Medical Center. Biomedical Computational Studies, Bar-Ilan University. Postdoctoral fellowship, University of Pennsylvania.
Her research focuses on AKI, immune-related kidney complications, and chronic kidney disease. She has authored many publications. She is a member of the American Society of Nephrology and a board member of the Israeli Society of Nephrology and Hypertension.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.